This HTML5 document contains 288 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n5http://linked.opendata.cz/resource/drugbank/mixture/
n26http://www.drugs.com/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/bindingdb/
n27http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/kegg-drug/
n25http://www.rxlist.com/cgi/generic/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/drugbank/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00999/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00999
rdf:type
n3:Drug
n3:description
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. [PubChem]
n3:dosage
n10:271B4DE4-363D-11E5-9242-09173F13E4C5 n10:271B4DE5-363D-11E5-9242-09173F13E4C5 n10:271B4DE6-363D-11E5-9242-09173F13E4C5 n10:271B4DE1-363D-11E5-9242-09173F13E4C5 n10:271B4DE2-363D-11E5-9242-09173F13E4C5 n10:271B4DE3-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5.6 and 14.8 hours
n3:indication
For the treatment of high blood pressure and management of edema.
n3:manufacturer
n4:271B4DB4-363D-11E5-9242-09173F13E4C5 n4:271B4DB5-363D-11E5-9242-09173F13E4C5 n4:271B4DB2-363D-11E5-9242-09173F13E4C5 n4:271B4DB3-363D-11E5-9242-09173F13E4C5 n4:271B4DB8-363D-11E5-9242-09173F13E4C5 n4:271B4DB6-363D-11E5-9242-09173F13E4C5 n4:271B4DB7-363D-11E5-9242-09173F13E4C5 n4:271B4DA4-363D-11E5-9242-09173F13E4C5 n4:271B4DA5-363D-11E5-9242-09173F13E4C5 n4:271B4DA2-363D-11E5-9242-09173F13E4C5 n4:271B4DA3-363D-11E5-9242-09173F13E4C5 n4:271B4DA8-363D-11E5-9242-09173F13E4C5 n4:271B4DA9-363D-11E5-9242-09173F13E4C5 n4:271B4DA6-363D-11E5-9242-09173F13E4C5 n4:271B4DA7-363D-11E5-9242-09173F13E4C5 n4:271B4DAC-363D-11E5-9242-09173F13E4C5 n4:271B4DAD-363D-11E5-9242-09173F13E4C5 n4:271B4DAA-363D-11E5-9242-09173F13E4C5 n4:271B4DAB-363D-11E5-9242-09173F13E4C5 n4:271B4DB0-363D-11E5-9242-09173F13E4C5 n4:271B4DB1-363D-11E5-9242-09173F13E4C5 n4:271B4DAE-363D-11E5-9242-09173F13E4C5 n4:271B4DAF-363D-11E5-9242-09173F13E4C5 n4:271B4D94-363D-11E5-9242-09173F13E4C5 n4:271B4D95-363D-11E5-9242-09173F13E4C5 n4:271B4D98-363D-11E5-9242-09173F13E4C5 n4:271B4D99-363D-11E5-9242-09173F13E4C5 n4:271B4D96-363D-11E5-9242-09173F13E4C5 n4:271B4D97-363D-11E5-9242-09173F13E4C5 n4:271B4D9C-363D-11E5-9242-09173F13E4C5 n4:271B4D9D-363D-11E5-9242-09173F13E4C5 n4:271B4D9A-363D-11E5-9242-09173F13E4C5 n4:271B4D9B-363D-11E5-9242-09173F13E4C5 n4:271B4DA0-363D-11E5-9242-09173F13E4C5 n4:271B4DA1-363D-11E5-9242-09173F13E4C5 n4:271B4D9E-363D-11E5-9242-09173F13E4C5 n4:271B4D9F-363D-11E5-9242-09173F13E4C5 n4:271B4D91-363D-11E5-9242-09173F13E4C5 n4:271B4D92-363D-11E5-9242-09173F13E4C5 n4:271B4D8F-363D-11E5-9242-09173F13E4C5 n4:271B4D90-363D-11E5-9242-09173F13E4C5 n4:271B4D93-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00999 n27:DB00999
dcterms:title
Hydrochlorothiazide
adms:identifier
n18:Hydrochlorothiazide n19:DB00999 n20:13076 n21:PA449899 n22:D00340 n23:0378-3603-01
n3:mechanismOfAction
Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.
n3:packager
n4:271B4D4A-363D-11E5-9242-09173F13E4C5 n4:271B4D48-363D-11E5-9242-09173F13E4C5 n4:271B4D5E-363D-11E5-9242-09173F13E4C5 n4:271B4D5C-363D-11E5-9242-09173F13E4C5 n4:271B4D5D-363D-11E5-9242-09173F13E4C5 n4:271B4D84-363D-11E5-9242-09173F13E4C5 n4:271B4D5A-363D-11E5-9242-09173F13E4C5 n4:271B4D85-363D-11E5-9242-09173F13E4C5 n4:271B4D5B-363D-11E5-9242-09173F13E4C5 n4:271B4D58-363D-11E5-9242-09173F13E4C5 n4:271B4D59-363D-11E5-9242-09173F13E4C5 n4:271B4D56-363D-11E5-9242-09173F13E4C5 n4:271B4D57-363D-11E5-9242-09173F13E4C5 n4:271B4D54-363D-11E5-9242-09173F13E4C5 n4:271B4D55-363D-11E5-9242-09173F13E4C5 n4:271B4D52-363D-11E5-9242-09173F13E4C5 n4:271B4D53-363D-11E5-9242-09173F13E4C5 n4:271B4D50-363D-11E5-9242-09173F13E4C5 n4:271B4D51-363D-11E5-9242-09173F13E4C5 n4:271B4D4E-363D-11E5-9242-09173F13E4C5 n4:271B4D4F-363D-11E5-9242-09173F13E4C5 n4:271B4D46-363D-11E5-9242-09173F13E4C5 n4:271B4D47-363D-11E5-9242-09173F13E4C5 n4:271B4D44-363D-11E5-9242-09173F13E4C5 n4:271B4D45-363D-11E5-9242-09173F13E4C5 n4:271B4D41-363D-11E5-9242-09173F13E4C5 n4:271B4D43-363D-11E5-9242-09173F13E4C5 n4:271B4D3F-363D-11E5-9242-09173F13E4C5 n4:271B4D40-363D-11E5-9242-09173F13E4C5 n4:271B4D62-363D-11E5-9242-09173F13E4C5 n4:271B4D63-363D-11E5-9242-09173F13E4C5 n4:271B4D60-363D-11E5-9242-09173F13E4C5 n4:271B4D61-363D-11E5-9242-09173F13E4C5 n4:271B4D42-363D-11E5-9242-09173F13E4C5 n4:271B4D72-363D-11E5-9242-09173F13E4C5 n4:271B4D73-363D-11E5-9242-09173F13E4C5 n4:271B4D70-363D-11E5-9242-09173F13E4C5 n4:271B4D71-363D-11E5-9242-09173F13E4C5 n4:271B4D6E-363D-11E5-9242-09173F13E4C5 n4:271B4D6F-363D-11E5-9242-09173F13E4C5 n4:271B4D6C-363D-11E5-9242-09173F13E4C5 n4:271B4D6D-363D-11E5-9242-09173F13E4C5 n4:271B4D6A-363D-11E5-9242-09173F13E4C5 n4:271B4D6B-363D-11E5-9242-09173F13E4C5 n4:271B4D68-363D-11E5-9242-09173F13E4C5 n4:271B4D69-363D-11E5-9242-09173F13E4C5 n4:271B4D66-363D-11E5-9242-09173F13E4C5 n4:271B4D67-363D-11E5-9242-09173F13E4C5 n4:271B4D64-363D-11E5-9242-09173F13E4C5 n4:271B4D65-363D-11E5-9242-09173F13E4C5 n4:271B4D82-363D-11E5-9242-09173F13E4C5 n4:271B4D83-363D-11E5-9242-09173F13E4C5 n4:271B4D80-363D-11E5-9242-09173F13E4C5 n4:271B4D81-363D-11E5-9242-09173F13E4C5 n4:271B4D7E-363D-11E5-9242-09173F13E4C5 n4:271B4D7F-363D-11E5-9242-09173F13E4C5 n4:271B4D7C-363D-11E5-9242-09173F13E4C5 n4:271B4D7D-363D-11E5-9242-09173F13E4C5 n4:271B4D7A-363D-11E5-9242-09173F13E4C5 n4:271B4D7B-363D-11E5-9242-09173F13E4C5 n4:271B4D78-363D-11E5-9242-09173F13E4C5 n4:271B4D2D-363D-11E5-9242-09173F13E4C5 n4:271B4D79-363D-11E5-9242-09173F13E4C5 n4:271B4D2E-363D-11E5-9242-09173F13E4C5 n4:271B4D76-363D-11E5-9242-09173F13E4C5 n4:271B4D2B-363D-11E5-9242-09173F13E4C5 n4:271B4D77-363D-11E5-9242-09173F13E4C5 n4:271B4D2C-363D-11E5-9242-09173F13E4C5 n4:271B4D74-363D-11E5-9242-09173F13E4C5 n4:271B4D29-363D-11E5-9242-09173F13E4C5 n4:271B4D75-363D-11E5-9242-09173F13E4C5 n4:271B4D2A-363D-11E5-9242-09173F13E4C5 n4:271B4D27-363D-11E5-9242-09173F13E4C5 n4:271B4D28-363D-11E5-9242-09173F13E4C5 n4:271B4D3D-363D-11E5-9242-09173F13E4C5 n4:271B4D3E-363D-11E5-9242-09173F13E4C5 n4:271B4D3B-363D-11E5-9242-09173F13E4C5 n4:271B4D3C-363D-11E5-9242-09173F13E4C5 n4:271B4D39-363D-11E5-9242-09173F13E4C5 n4:271B4D3A-363D-11E5-9242-09173F13E4C5 n4:271B4D37-363D-11E5-9242-09173F13E4C5 n4:271B4D38-363D-11E5-9242-09173F13E4C5 n4:271B4D35-363D-11E5-9242-09173F13E4C5 n4:271B4D36-363D-11E5-9242-09173F13E4C5 n4:271B4D33-363D-11E5-9242-09173F13E4C5 n4:271B4D34-363D-11E5-9242-09173F13E4C5 n4:271B4D31-363D-11E5-9242-09173F13E4C5 n4:271B4D32-363D-11E5-9242-09173F13E4C5 n4:271B4D2F-363D-11E5-9242-09173F13E4C5 n4:271B4D30-363D-11E5-9242-09173F13E4C5 n4:271B4D8D-363D-11E5-9242-09173F13E4C5 n4:271B4D8E-363D-11E5-9242-09173F13E4C5 n4:271B4D8B-363D-11E5-9242-09173F13E4C5 n4:271B4D8C-363D-11E5-9242-09173F13E4C5 n4:271B4D5F-363D-11E5-9242-09173F13E4C5 n4:271B4D89-363D-11E5-9242-09173F13E4C5 n4:271B4D8A-363D-11E5-9242-09173F13E4C5 n4:271B4D87-363D-11E5-9242-09173F13E4C5 n4:271B4D88-363D-11E5-9242-09173F13E4C5 n4:271B4D4D-363D-11E5-9242-09173F13E4C5 n4:271B4D86-363D-11E5-9242-09173F13E4C5 n4:271B4D4B-363D-11E5-9242-09173F13E4C5 n4:271B4D4C-363D-11E5-9242-09173F13E4C5 n4:271B4D49-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
n3:synonym
Esidrix HCTZ Microzide
n3:toxicity
The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.
n12:hasAHFSCode
n13:40-28-20
n3:foodInteraction
Avoid alcohol. Avoid excess salt/sodium unless otherwise instructed by your physician. Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication. Take with food. Increase potassium intake; add a banana or orange juice; unless instructed otherwise. Avoid natural licorice.
n3:mixture
n5:271B4D26-363D-11E5-9242-09173F13E4C5 n5:271B4D0C-363D-11E5-9242-09173F13E4C5 n5:271B4D0F-363D-11E5-9242-09173F13E4C5 n5:271B4D10-363D-11E5-9242-09173F13E4C5 n5:271B4D0D-363D-11E5-9242-09173F13E4C5 n5:271B4D0E-363D-11E5-9242-09173F13E4C5 n5:271B4D13-363D-11E5-9242-09173F13E4C5 n5:271B4D14-363D-11E5-9242-09173F13E4C5 n5:271B4D11-363D-11E5-9242-09173F13E4C5 n5:271B4D12-363D-11E5-9242-09173F13E4C5 n5:271B4D17-363D-11E5-9242-09173F13E4C5 n5:271B4D18-363D-11E5-9242-09173F13E4C5 n5:271B4D15-363D-11E5-9242-09173F13E4C5 n5:271B4D16-363D-11E5-9242-09173F13E4C5 n5:271B4D1B-363D-11E5-9242-09173F13E4C5 n5:271B4D1C-363D-11E5-9242-09173F13E4C5 n5:271B4D19-363D-11E5-9242-09173F13E4C5 n5:271B4D1A-363D-11E5-9242-09173F13E4C5 n5:271B4D1F-363D-11E5-9242-09173F13E4C5 n5:271B4D20-363D-11E5-9242-09173F13E4C5 n5:271B4D1D-363D-11E5-9242-09173F13E4C5 n5:271B4D1E-363D-11E5-9242-09173F13E4C5 n5:271B4D23-363D-11E5-9242-09173F13E4C5 n5:271B4D24-363D-11E5-9242-09173F13E4C5 n5:271B4D21-363D-11E5-9242-09173F13E4C5 n5:271B4D22-363D-11E5-9242-09173F13E4C5 n5:271B4D25-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
67.9%
n3:synthesisReference
Frederic J. Nugent, John K. C. Yen, "Process for preparing the combination products of triamterene and hydrochlorothiazide." U.S. Patent US4804540, issued July, 1987.
n7:hasConcept
n8:M0010703
foaf:page
n25:hctz.htm n26:hctz.html
n3:IUPAC-Name
n6:271B4DEB-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4DF1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4DF0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4DED-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4DEE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4DEF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4DE9-363D-11E5-9242-09173F13E4C5 n6:271B4E01-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4DE7-363D-11E5-9242-09173F13E4C5 n6:271B4DEA-363D-11E5-9242-09173F13E4C5 n6:271B4E03-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4DE8-363D-11E5-9242-09173F13E4C5 n6:271B4E04-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B4E06-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n16:C03AA03
n3:H-Bond-Acceptor-Count
n6:271B4DF7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4DF8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4DF2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4DF3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4DF5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4DF4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4DF6-363D-11E5-9242-09173F13E4C5
n3:absorption
50-60%
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n6:271B4E05-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
58-93-5
n3:category
n3:containedIn
n9:271B4DD2-363D-11E5-9242-09173F13E4C5 n9:271B4DD3-363D-11E5-9242-09173F13E4C5 n9:271B4DD0-363D-11E5-9242-09173F13E4C5 n9:271B4DD1-363D-11E5-9242-09173F13E4C5 n9:271B4DCE-363D-11E5-9242-09173F13E4C5 n9:271B4DCF-363D-11E5-9242-09173F13E4C5 n9:271B4DCC-363D-11E5-9242-09173F13E4C5 n9:271B4DCD-363D-11E5-9242-09173F13E4C5 n9:271B4DB9-363D-11E5-9242-09173F13E4C5 n9:271B4DBA-363D-11E5-9242-09173F13E4C5 n9:271B4DC9-363D-11E5-9242-09173F13E4C5 n9:271B4DD4-363D-11E5-9242-09173F13E4C5 n9:271B4DC7-363D-11E5-9242-09173F13E4C5 n9:271B4DC8-363D-11E5-9242-09173F13E4C5 n9:271B4DC5-363D-11E5-9242-09173F13E4C5 n9:271B4DC6-363D-11E5-9242-09173F13E4C5 n9:271B4DC3-363D-11E5-9242-09173F13E4C5 n9:271B4DC4-363D-11E5-9242-09173F13E4C5 n9:271B4DC1-363D-11E5-9242-09173F13E4C5 n9:271B4DC2-363D-11E5-9242-09173F13E4C5 n9:271B4DBF-363D-11E5-9242-09173F13E4C5 n9:271B4DC0-363D-11E5-9242-09173F13E4C5 n9:271B4DBD-363D-11E5-9242-09173F13E4C5 n9:271B4DBE-363D-11E5-9242-09173F13E4C5 n9:271B4DBB-363D-11E5-9242-09173F13E4C5 n9:271B4DBC-363D-11E5-9242-09173F13E4C5 n9:271B4DDF-363D-11E5-9242-09173F13E4C5 n9:271B4DE0-363D-11E5-9242-09173F13E4C5 n9:271B4DDD-363D-11E5-9242-09173F13E4C5 n9:271B4DDE-363D-11E5-9242-09173F13E4C5 n9:271B4DDB-363D-11E5-9242-09173F13E4C5 n9:271B4DDC-363D-11E5-9242-09173F13E4C5 n9:271B4DD9-363D-11E5-9242-09173F13E4C5 n9:271B4DDA-363D-11E5-9242-09173F13E4C5 n9:271B4DD7-363D-11E5-9242-09173F13E4C5 n9:271B4DD8-363D-11E5-9242-09173F13E4C5 n9:271B4DD5-363D-11E5-9242-09173F13E4C5 n9:271B4DD6-363D-11E5-9242-09173F13E4C5 n9:271B4DCA-363D-11E5-9242-09173F13E4C5 n9:271B4DCB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4DFD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4DFF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4E00-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B4E02-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4DFC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4DFB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4DFE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4DEC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4DF9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4DFA-363D-11E5-9242-09173F13E4C5